Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial
- Citation:
- J Natl Cancer Inst vol 116 (1) 115-26
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Book Volume:
- 13
- Parents:
- None
- Children:
- None
- Program:
- TRP
- Primary Committee:
- Correl Sci NOS
- Sec. Committees:
- GU
- Pharmas:
- Sanofi-Aventis
- Grants:
- U10CA180821, U10CA180882, U24 CA196171, UG1CA233180, UG1CA233253, UG1CA233290, U10CA180863 (Canadian Cancer Trials Group) , R01 CA256157, R01 CA249279, W81XWH-17-1-0653, R37 CA24148601A1, 5U01CA157703
- Corr. Author:
- Authors:
- Takayuki Sumiyoshi Xiaofei Wang Evan W Warner Andrea Sboner Matti Annala Michael Sigouros Kevin Beja Kei Mizuno Shengyu Ku Ladan Fazli James Eastham Mary-Ellen Taplin Jeffrey Simko Susan Halabi Michael J Morris Martin E Gleave Alexander W Wyatt Himisha Beltran
- Networks:
- LAPS-MA036, LAPS-NY016
- Study
- CALGB-90203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: